- Approval Id
- 2ca27d2a0350c37f
- Drug Name
- GP-ACETAZOLAMIDE TABLET 250MG
- Product Name
- GP-ACETAZOLAMIDE TABLET 250MG
- Approval Number
- SIN16860P
- Approval Date
- 2023-09-13
- Registrant
- GOLDPLUS UNIVERSAL PTE LTD
- Licence Holder
- GOLDPLUS UNIVERSAL PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- TABLET
- Dosage
- **4.7 Dosage**
Chronic simple (open angle) glaucoma: 250mg 1 to 4 times daily. A complementary effect has been noted when acetazolamide was used with miotics or mydriatics as the case demanded.
Secondary glaucoma and preoperative treatment of some cases of acute congestive (closed angle) glaucoma: 250mg every 4 hours.
Epilepsy 8 to 30 mg/kg (375 to 1000 mg) daily in divided doses. To alkalinize the urine 250mg every 4 to 6 hours.
- Route Of Administration
- ORAL
- Indication Info
- **4.1 Indications**
To decrease ocular aqueous humor secretion in glaucoma (chronic, simple and secondary types). Also used as an adjunct in the treatment of selected cases of epilepsy. To alkalinise the urine in selected cases of salicylate overdosage.
- Contraindications
- **4.2 Contraindications**
Depressed sodium and/or potassium blood levels, in renal failure, adrenal gland failure, metabolic acidosis, and some cases of hepatic cirrhosis, severe glaucoma due to peripheral anterior synechias or in hemorrhagic glaucoma. Long term use in chronic noncongestive angle closure glaucoma is contraindicated.
Studies on acetazolamide in mice and rats have consistently demonstrated embryocidal and teratogenic effects at doses in excess of 10 times the human dose. There is no evidence of these effects in humans; however, acetazolamide should not be used in pregnancy, unless the anticipated benefits outweigh these potential hazards and are not attainable in other ways.
- Atc Code
- S01EC01
- Atc Item Name
- acetazolamide
- Pharma Manufacturer Name
- GOLDPLUS UNIVERSAL PTE LTD
- Company Detail Path
- /organization/7cb5b69d6eb36564/goldplus-universal-pte-ltd
